Ambagon Therapeutics Appoints Gideon Bollag, Ph.D., to Scientific Advisory Board
Ambagon Therapeutics Launches with $85 Million Series A to Advance Pioneering Molecular Glue Platform and Progress Pipeline
2022 Class of Emerging Companies
Top Life Sciences Startups to Watch in 2023
Ambagon: creating molecular glues for disordered proteins
Molecular glues to stabilise protein-protein interactions
Current Opinion in Chemical Biology. 2022.
Macrocycle-stabilization of its interaction with 14-3-3 increases plasma membrane localization and activity of CFTR
Nat Commun. 2022.
Reversible Covalent Imine-tethering for Selective Stabilization of 14-3-3 Hub Protein Interactions
J. Am. Chem. Soc. 2021
Fragment-based Differential Targeting of PPI Stabilizer Interfaces
J. Med. Chem. 2020
Structure-based Evolution of a Promiscuous Inhibitor to a Selective Stabilizer of Protein–protein Interactions
Nat Commun. 2020
Site-directed Fragment-Based Screening for the Discovery of Protein–protein Interaction Stabilizers.
J. Am. Chem. Soc. 2019
Stabilization of Physical RAF/14-3-3 Interaction by Cotylenin A as Treatment Strategy for RAS Mutant Cancers
ACS Chem Biol. 2013